Codexis, Inc. (NASDAQ: CDXS) reported Q2 EPS of ($0.22), $0.07 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $6.6 million versus the consensus estimate of $8.5 million.

"I am pleased to announce that Codexis is now set to deliver a positive cash flow result in 2014, well ahead of our previous expectations. After delivering results in line with our expectations in the second quarter of 2014, and based on our recently announced Technology Collaboration and Licensing Agreement with GSK, we are revising all of our financial guidance metrics for fiscal year 2014," said John Nicols, President and CEO of Codexis. "We look forward to executing on the new agreement with GSK, continuing to deliver growth from our biocatalyst opportunity pipeline, as well as working to bring in additional CodeEvolver® protein engineering license deals with other innovative blue chip customers in the future."

For earnings history and earnings-related data on Codexis, Inc. (CDXS) click here.